The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question....
Sábháilte in:
| Príomhchruthaitheoirí: | , , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
MDPI AG,
2022-02-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
| Gairmuimhir: |
A1234.567 |
|---|---|
| Cóip 1 | Ar fáil |